Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02218099
Recruitment Status : Completed
First Posted : August 15, 2014
Last Update Posted : May 22, 2019
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe B.V. )

Brief Summary:

This study consists of two parts.

Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.

Part 2 evaluates the PK, PD, and safety and tolerability of multiple doses of ASP8232 compared with placebo in Type 2 Diabetes Mellitus (T2DM) subjects with Chronic Kidney Disease (CKD).


Condition or disease Intervention/treatment Phase
Healthy Subjects Pharmacokinetics of ASP8232 Pharmacodynamics of ASP8232 Chronic Kidney Disease (CKD) Type 2 Diabetes Mellitus (T2DM) Drug: ASP8232 Drug: Placebo Phase 1 Phase 2

Detailed Description:

This is a two-part study. Part 1 compares the pharmacokinetics (PK), pharmacodynamics (PD) and safety and tolerability of ASP8232 in healthy subjects with subjects with different degrees of renal impairment; Part 2 is a multiple-dose, placebo-controlled study to evaluate the PK, PD and safety and tolerability of multiple doses of ASP8232 in T2DM subjects with CKD.

Part 1:

Subjects reside in the clinic for 9 days, receiving a single oral dose of ASP8232 on Day 1 under fasted conditions followed by a 168-hours blood and urine PK/PD sampling period. Subjects are discharged on Day 8 and return to the clinic on Days 10, 12, 14, 21, 28, and 42 for the collection of blood PK/PD samples. An End of Study Visit (ESV) takes place after the last PK sample is collected on Day 56.

Part 2:

Subjects are admitted to the clinic on Day -2 in order to collect PD urine samples before dosing begins on Day 1. Subjects receive multiple oral doses of ASP8232 or placebo for 28 days. They are discharged on Day 8 and return to the clinic on Days 14 and 21, and Days 27 to 29 for blood PK/PD and urine PD samples. An ESV takes place 14 to 28 days after the last PK/PD sample is collected.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase 1 Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 (Part 1) and a Multiple Dose, Placebo-controlled Exploratory Safety, Pharmacokinetic and Pharmacodynamic Study in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease (Part 2)
Actual Study Start Date : September 16, 2013
Actual Primary Completion Date : September 9, 2014
Actual Study Completion Date : September 9, 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
Experimental: 1: Single dose of ASP8232
Subjects receive a single oral dose of ASP8232
Drug: ASP8232
Oral

Experimental: 2: Multiple doses of ASP8232 or placebo
Subjects receive multiple oral doses of ASP8232 or placebo
Drug: ASP8232
Oral

Drug: Placebo
Oral




Primary Outcome Measures :
  1. Part 1: PK of ASP8232 in plasma measured by Area Under the concentration-time Curve (AUC) from zero to infinity with extrapolation of the terminal phase (AUCinf) [ Time Frame: Day 1 to Day 56 ]
  2. Part 1: PK of ASP8232 in plasma measured by AUC from zero up to last time point of observation (AUClast) [ Time Frame: Day 1 to Day 56 ]
  3. Part 1: PK of ASP8232 in plasma measured by AUC from zero up to last time point of observation, unbound fraction (AUClast,u) [ Time Frame: Day 1 to Day 56 ]
  4. Part 1: PK of ASP8232 in plasma measured by AUC from 0 to infinity with extrapolation of the terminal phase, unbound fraction (AUCinf,u) [ Time Frame: Day 1 to Day 56 ]
  5. Part 1: PK of ASP8232 in plasma measured by maximum concentration (Cmax) [ Time Frame: Day 1 to Day 56 ]
  6. Part 1: PK of ASP8232 in plasma measured by maximum concentration, unbound fraction (Cmax,u) [ Time Frame: Day 1 to Day 56 ]
  7. Part 2: Safety and tolerability of ASP8232 measured by nature, frequency and severity of AEs, vital signs, safety laboratory tests, routine ECG [ Time Frame: Screening to End of Study Visit (ESV) ]

Secondary Outcome Measures :
  1. Part 1: PK profile of ASP8232 in plasma [ Time Frame: Day 1 to Day 56 ]
    apparent total plasma clearance of drug after oral administration (CL/F), renal clearance based on unbound plasma concentrations (CLu/F), fraction unbound (fu), lag-time (time delay between drug administration and first observed concentration above LOQ in plasma) (tlag), time to reach Cmax (tmax), terminal elimination half-life (t1/2), apparent volume of distribution during terminal phase after oral administration (Vz/F), apparent volume of distribution during terminal phase after oral administration, unbound fraction (Vz,u/F)

  2. Part 1: PK profile of ASP8232 in urine [ Time Frame: Day -1 to Day 8 ]
    renal clearance (CLR), CLR unbound fraction (CLR,u), amount of drug excreted in urine from time point 0 to time point 24 h (Ae0-24h), percent of drug excreted in urine from time point 0 to time point 24 h (Ae0-24h%), cumulative amount of drug excreted in urine from time of dosing up to the collection time of the last measurable concentration (Aelast), percent of drug dose excreted in urine (Aelast) from time of dosing up to the collection time of the last measurable concentration (Aelast%), cumulative amount of drug excreted in urine from time of dosing extrapolated to time infinity (Aeinf), percent of drug dose excreted in urine (Aeinf) from time of dosing extrapolated to time infinity (Aeinf%)

  3. Part 1: PD of Vascular adhesion protein-1 (VAP-1) activity in plasma [ Time Frame: Day -1 to Day 56 ]
    maximum activity (Rmax), maximum activity in percent (Rmax%), time to attain maximal Response (tmax, R), average response over the first 24 h after dosing (Ravg, 0-24h)

  4. Part 1: PD of Total antioxidant status (TAS) in serum [ Time Frame: Day -1 to Day 56 ]
    Rmax, Rmax%, tmax, R, Ravg, 0-24h

  5. Part 1: Safety and tolerability of ASP8232 [ Time Frame: Screening to Day 56 ]
    nature, frequency and severity of Adverse Events (AEs), vital signs, safety laboratory tests, routine Electrocardiogram (ECG)

  6. Part 2: PK profile of ASP8232 in plasma [ Time Frame: Day 1 to Day 29 ]
    free drug fraction (fu), area under the concentration-time curve from the time of dosing to the start of the next dosing interval (AUCtau), area under the concentration-time curve during a dosing interval at steady state, unbound fraction (AUCtau,u), tmax, Cmax, Cmax,u, CL/F, CLu/F, Peak Trough Ratio (PTR), concentration immediately prior to dosing at multiple dosing (Ctrough), Ctrough, unbound (Ctrough, u)

  7. Part 2: PK profile of ASP8232 in urine [ Time Frame: Day 1 to Day 8 and Day 28 to Day 29 ]
    amount of unchanged drug excreted in urine over a dosing interval in steady state (Aetau), amount of unchanged drug excreted in urine over a dosing interval in steady state in % (Aetau%), CLR, CLR,u

  8. Part 2: PD of VAP-1 activity in plasma [ Time Frame: Day -2 to Day 21 and Day 28 to ESV ]
    Rmax and Rmax%

  9. Part 2: PD of TAS in serum [ Time Frame: Day -2 to Day 21 and Day 28 to ESV ]
    Rmax, Rmax%, tmax, R, Ravg, 0-24h

  10. Part 2: 24-hour urinary albumin excretion rate (UAER) [ Time Frame: Day -1, Day 7 and Day 28 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Main Inclusion: Part 1

  • Independent Ethics Committee (IEC)-approved written Informed Consent and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
  • Male subject and his female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the study period and for 28 days (or 5 half-lives of the study drug whichever is longer) after final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the study period and for at least 90 days after final study drug administration.
  • Female subject must be either:

    • post-menopausal (defined as at least one year without any menses) prior to screening, or
    • premenarchal prior to screening, or
    • documented surgically sterile or status post hysterectomy (at least 1 month before screening), or
    • if of childbearing potential, must have a negative urine pregnancy test at screening and must be using highly effective contraception. All females of childbearing potential will be required to use highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and throughout the study period and for 28 days (or 5 half-lives of the study drug whichever is longer) after final study drug administration.
  • Female subject must not be lactating, and must not be breast feeding at screening or during the study period and for 28 days [or 5 half-lives of the study drug whichever is longer] after final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period and for 28 days [or 5 half-lives of the study drug whichever is longer] after final study drug administration.
  • Subject agrees not to participate in another interventional study while on treatment.

Healthy Subjects:

  • Subject must have pre dose eGFR values (based on the MDRD method) at screening and day -1 higher or equal to 80 mL/min/1.73 m2.

Renal Impaired Subjects:

  • Subject must have pre dose eGFR values (based on the MDRD method) at screening and day -1 of 15 to < 30 mL/min/1.73 m2, 30 to

< 60 mL/min/1.73 m2 or 60 to < 80 mL/min/1.73 m2 for severe, moderate or mild renal impaired subjects, respectively.

Part 2 Inclusion:

  • Independent Ethics Committee (IEC)-approved written Informed Consent and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
  • Subject has either known or confirmed T2DM with CKD for at least 1 year [screening].
  • Subject is ≥ 35 and ≤ 80 years of age.
  • Male subject and his female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the study period and for 28 days (or 5 half-lives of the study drug whichever is longer) after final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the study period and for at least 90 days after final study drug administration.
  • Female subject must be either

    • post-menopausal (defined as at least one year without any menses) prior to Screening, or
    • premenarchal prior to screening, or
    • documented surgically sterile or status post hysterectomy (at least 1 month before screening), or
    • if of childbearing potential, must have a negative urine pregnancy test at screening and must be using highly effective contraception1. All females of childbearing potential will be required to use highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and throughout the study period and for 28 days (or 5 half-lives of the study drug whichever is longer) after final study drug administration.
  • Female subject must not be lactating, and must not be breast feeding at screening or during the study period and for 28 days (or 5 half-lives of the study drug whichever is longer) after final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period and for 28 days (or 5 half-lives of the study drug whichever is longer] after final study drug administration.
  • Subject is on a stable therapy with ACE inhibitors or ARB for at least 3 months [screening].
  • Subject is on a stable anti-hyperglycaemia therapy, e.g. with Metformin, SUD, TZD or DPP-4 inhibitor.
  • Subject's eGFR is between 15-60 mL/min/1.73 m2 (based on the MDRD method).
  • Subject's HbA1c level is lower than 7.5% at clinic admission on day -2.
  • Subject has a stable blood pressure for at least 3 to 6 months prior to enrolment.
  • Subject's UACR is higher than 30 mg/g at clinic admission on day -2.

Part 1 Exclusion:

All Subjects:

  • Female subject who has been pregnant within 6 months before screening or breast feeding within 3 months before screening.
  • Subject has a known or suspected hypersensitivity to ASP8232, or any components of the formulation used.
  • Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Subject has Gilbert's syndrome.
  • Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check in.
  • Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the Clinical Unit.
  • Subject has a history of drinking more than 21 units of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) (> 14 units of alcohol for female subjects) within 3 months prior to admission to the Clinical Unit.
  • Subject uses drugs of abuse within 3 months prior to admission to the Clinical Unit.
  • Subject regularly uses any inducer of metabolism (e.g. barbiturates, rifampin ) in the 3 months prior to admission to the Clinical Unit.
  • Subject had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission on day -1.
  • Subject has positive serology test for Hepatitis B Surface Antigen (HBsAg), anti-Hepatitis A virus (anti-HAV [IgM]), anti-Hepatitis C virus (anti-HCV) or anti- Human immunodeficiency virus 1 + 2 (anti-HIV 1+2).
  • Subject participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half-lives whichever is longer, prior to the initiation of screening.
  • Subject is an employee of the Astellas Group or Clinical Research Organization (CRO) involved in the study.

Healthy Subjects:

  • Subject has any of the liver function tests (Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], total bilirubin [TBL]) above the upper limit of normal. In such a case the assessment may be repeated once [day -1].
  • Subject has a mean QTc(F) interval of > 430 ms (for males) and > 450 ms (for females) at screening and day -1. If the mean QTc(F) exceeds the limits above, one additional triplicate electrocardiogram (ECG) can be taken. If this triplicate also gives abnormal result the subject should be excluded.
  • Subject uses any prescribed or non-prescribed drugs (including vitamins, hormone replacement therapy, natural and herbal remedies, e.g. St. John's Wort) in the 2 weeks prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day).

Renal Impaired Subjects:

  • Subject is on or requires hemodialysis or has received a kidney transplantation.
  • Subject has a supine mean systolic blood pressure < 90 or > 160 mmHg and a mean diastolic blood pressure < 50 or > 100 mmHg, or pulse rate < 40 or > 90 beats p/m, on screening and day -1. In such a case the assessment may be repeated once (day -1).
  • Subject has a mean QTc(F) interval of > 450 ms (for males) and > 470 ms (for females) at screening and day -1. If the mean QTc(F) exceeds the limits above, one additional triplicate ECG can be taken. If this triplicate also gives abnormal result the subject should be excluded.
  • Subject has not been on a stable dose of allowed concomitant medications for at least 2 weeks prior to day 1 and/or for whom dose changes are likely to occur during the study.
  • Subject requires or is likely to require any new concomitant medications during the course of the study.
  • Subject has obstructive uropathy or other causes of renal impairment not related to parenchymal renal disorder and/or disease of the kidney.
  • Subject has renal disease secondary to malignancy.
  • Subject has a fluctuating or rapidly deteriorating renal function within 4 weeks prior to screening, as indicated by strongly varying or worsening of clinical and/or laboratory signs of renal impairment within the screening period.
  • Subject has any of the liver function tests (ALT, AST, TBL) out of range. In such a case the assessment may be repeated once [day -1].

    • ALT or AST > 2 x upper limit of normal (ULN)
    • TBL > 1.5 x ULN

Part 2 Exclusion

  • Female subject who has been pregnant within 6 months prior to screening assessment or breast feeding within 3 months prior to screening.
  • Subject has known or suspected hypersensitivity to ASP8232 or sinistrin, or any components of the formulation used.
  • Subject has participated in part 1 of the 8232-CL-0002 study.
  • Subject has a mean QTc(F) interval of > 450 ms (for males) and > 470 ms (for females) at screening and day -2. If the mean QTc(F) exceeds the limits above, one additional triplicate ECG can be taken. If this triplicate also gives abnormal result the subject should be excluded.
  • Subject has a pulse < 40 or > 90 bpm; mean systolic blood pressure >140 mmHg; mean diastolic blood pressure > 90 mmHg (measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically) at screening and day -2. In such a case the assessment may be repeated once [day -2].
  • Subject is on or requires hemodialysis or has received a kidney transplantation.
  • Subject has not been on a stable dose of allowed concomitant medications for at least 2 weeks prior to day 1 and/or for whom dose changes are likely to occur during the study.
  • Subject who requires or is likely to require any new concomitant medications during the course of the study.
  • Subject who has obstructive uropathy or other causes of renal impairment not related to parenchymal renal disorder and/or disease of the kidney.
  • Subject who has renal disease secondary to malignancy.
  • Subject who has a fluctuating or rapidly deteriorating renal function within 4 weeks prior to the study, as indicated by strongly varying or worsening of clinical and/or laboratory signs of renal impairment within the screening period.
  • Subject has type 1 diabetes mellitus.
  • Subject with any of the liver function tests (ALT, AST, TBL) out of range as indicated below. In such a case the assessment may be repeated once [day -2].

    • ALT or AST > 2 x ULN
    • Total bilirubin > 1.5 x ULN
  • Subject has had myocardial infarct or stroke within 6 months prior to screening.
  • The subject has Gilbert's Syndrome.
  • Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • The subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within one week prior to clinic admission on day -2.
  • Subject has a history of drinking more than 21 units of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) (> 14 units of alcohol for female subjects) within 3 months prior to admission to the Clinical Unit.
  • Subject uses of drugs of abuse within 3 months prior to admission to the Clinical Unit.
  • Subject regularly uses any inducer of metabolism (e.g. barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit.
  • Subject had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission on day -2.
  • Subject has positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.
  • Subject participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half-lives whichever is longer, prior to the initiation of screening.
  • Subject is employee of the Astellas Group or CRO involved in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02218099


Locations
Layout table for location information
Bulgaria
Site: 35901
Sofia, Bulgaria, 1612
Moldova, Republic of
Site: 37301
Chisinau, Moldova, Republic of
Romania
Site: 40001
Bucharest, Romania, 10731
Sponsors and Collaborators
Astellas Pharma Europe B.V.
Investigators
Layout table for investigator information
Study Director: Central contact Astellas Pharma Europe B.V.
Additional Information:
Layout table for additonal information
Responsible Party: Astellas Pharma Europe B.V.
ClinicalTrials.gov Identifier: NCT02218099    
Other Study ID Numbers: 8232-CL-0002
2013-000680-89 ( EudraCT Number )
First Posted: August 15, 2014    Key Record Dates
Last Update Posted: May 22, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Europe B.V. ):
ASP8232
Multiple doses
Phase 1
Single dose
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Urologic Diseases
Renal Insufficiency